Survival of BCR-ABL+ inv(16)+ AML
| Outcome . | Allo-HSCT . | No allo-HSCT . | Total . |
|---|---|---|---|
| Alive, n (%) | 6 (67) | 10 (71) | 16 (70) |
| Dead, n (%) | 3 (33) | 4 (29)* | 7 (30) |
| Total | 9 | 14 | 23 |
| Outcome . | Allo-HSCT . | No allo-HSCT . | Total . |
|---|---|---|---|
| Alive, n (%) | 6 (67) | 10 (71) | 16 (70) |
| Dead, n (%) | 3 (33) | 4 (29)* | 7 (30) |
| Total | 9 | 14 | 23 |
Long-term survival of patients with BCR-ABL+ AML with concurrent inv(16) from the literature. The table shows a substantial proportion of long-term survivors, even without allogeneic HSCT. The numbers represent absolute patient cases.
1 early death.